retatrutide not losing weight for loss: Study shows 30% body weight loss VisualAbstract: Retatrutide reduces body weight

Over half of users said their GLP-1s were difficult to afford, and many who had stopped the treatment cited the cost

Market Outlook and Strategic Insights The obesity and weight loss treatment landscape will undergo substantial transformation in the coming years

GI side effects and dose relationship Gastrointestinal symptoms are the most common adverse events reported with retatrutide, and they follow a clear dose-dependent pattern

Tirzepatide offers the best balance: highest efficacy among approved options, best tolerability (31% nausea), and lower cost than Semaglutide

Limited-Time Offer: New patients can receive the initial two doses (0.25 mg and 0.5 mg) for only $199 per month between November 17, 2025, and March 31, 2026

Along with making it harder to get a good nights sleep, OSA may negatively affect weight management and blood sugar control, which can already be challenging for people with PCOS